Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Referencesv9
  2. Primary and study completion dates changed from estimate of Sep 2010 to Jun 2011
    • Trial status: Active, Not Recruiting to Completed
    v8
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Sep 2010
    • Study completion date: Dec 2008 to Sep 2010
    • Site details revised at 2 of 2 sites
    v7
  4. Study completion date: Dec 2007 to Dec 2008
    • Secondary endpoints: details revised at 3 of 3 entries
    v6
  5. Study completion date: Jun 2006 to Dec 2007
    • Site contacts updated at 1 of 2 sites
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 1 to 2
    • Collaborators expanded, about 2 words
    v4
  2. Eligibility criteria expanded, about 1 wordv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2005
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Claudius Regaud
76 trials monitored
See 4 trials at risk
Glioma
1,259 trials monitored
See 92 trials at risk
Glioblastoma
714 trials monitored
See 56 trials at risk
The purpose of this study is to determine the efficacy by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy.
Trial Details
NCT Number NCT00209989
Lead Sponsor Institut Claudius Regaud
Collaborators: Janssen-Cilag Ltd.
Conditions
(from sponsor)		 Glioblastoma Multiforme
Related terms Glioblastoma
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov